{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:52:14Z","timestamp":1793674334375,"version":"4.5.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.nbd.2026.107452","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:31:28Z","timestamp":1778945488000},"page":"107452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Combination of CSF \u03b1-synuclein seed amplification assay and amyloid-\u03b242 predicts cognitive decline in Parkinson's disease"],"prefix":"10.1016","volume":"225","author":[{"given":"Qiang","family":"Qiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren","family":"Skudder-Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Toyota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenshi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2026.107452_bb0005","article-title":"Parkinson disease-associated cognitive impairment","volume":"7","author":"Aarsland","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.nbd.2026.107452_bb0010","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ana.26453","article-title":"\u03b1-Synuclein seed amplification in CSF and brain from patients with different brain distributions of pathological \u03b1-synuclein in the context of co-pathology and non-LBD diagnoses","volume":"92","author":"Arnold","year":"2022","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2026.107452_bb0015","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/mds.25844","article-title":"Time to redefine PD? Introductory statement of the MDS task force on the definition of Parkinson\u2019s disease","volume":"29","author":"Berg","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2026.107452_bb0020","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41596-022-00787-3","article-title":"Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid","volume":"18","author":"Concha-Marambio","year":"2023","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.nbd.2026.107452_bb0025","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208033","article-title":"Evaluation of ATN(PD) framework and biofluid markers to predict cognitive decline in early Parkinson disease","volume":"102","author":"Cousins","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2026.107452_bb0030","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S1474-4422(09)70238-8","article-title":"Neuropathological assessment of Parkinson\u2019s disease: refining the diagnostic criteria","volume":"8","author":"Dickson","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2026.107452_bb0035","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209699","article-title":"Long-term dementia risk in Parkinson disease","volume":"103","author":"Gallagher","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2026.107452_bb0040","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the unified Parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2026.107452_bb0045","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","article-title":"A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria","volume":"23","author":"H\u00f6glinger","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2026.107452_bb0050","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/bpa.12182","article-title":"Regional multiple pathology scores are associated with cognitive decline in Lewy body dementias","volume":"25","author":"Howlett","year":"2015","journal-title":"Brain Pathol."},{"key":"10.1016\/j.nbd.2026.107452_bb0055","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/ana.23659","article-title":"Neuropathologic substrates of Parkinson disease dementia","volume":"72","author":"Irwin","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2026.107452_bb0060","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nrn3549","article-title":"Parkinson\u2019s disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies","volume":"14","author":"Irwin","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.nbd.2026.107452_bb0065","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","article-title":"Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis","volume":"16","author":"Irwin","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2026.107452_bb0070","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ana.25811","article-title":"Evolution of Alzheimer\u2019s disease cerebrospinal fluid biomarkers in early Parkinson\u2019s disease","volume":"88","author":"Irwin","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2026.107452_bb0075","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nbd.2026.107452_bb0080","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1001\/jamaneurol.2014.2704","article-title":"Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease","volume":"72","author":"Kalia","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.nbd.2026.107452_bb0085","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00401-016-1552-2","article-title":"CSF biomarkers associated with disease heterogeneity in early Parkinson\u2019s disease: the Parkinson\u2019s progression markers Initiative study","volume":"131","author":"Kang","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2026.107452_bb0090","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1212\/01.WNL.0000165987.89198.65","article-title":"Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both","volume":"64","author":"Kraybill","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2026.107452_bb0095","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/acn3.644","article-title":"The Parkinson\u2019s progression markers initiative (PPMI) - establishing a PD biomarker cohort","volume":"5","author":"Marek","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.nbd.2026.107452_bb0100","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S1474-4422(25)00157-7","article-title":"Diagnostic and prognostic value of \u03b1-synuclein seed amplification assay kinetic measures in Parkinson\u2019s disease: a longitudinal cohort study","volume":"24","author":"Orr\u00fa","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2026.107452_bb0105","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/s41591-023-02450-0","article-title":"Cognitive effects of Lewy body pathology in clinically unimpaired individuals","volume":"29","author":"Palmqvist","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2026.107452_bb0110","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","article-title":"The Parkinson progression marker Initiative (PPMI)","volume":"95","author":"Parkinson Progression Marker Initiative","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.nbd.2026.107452_bb0115","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mds.24962","article-title":"The neuropathology of genetic Parkinson\u2019s disease","volume":"27","author":"Poulopoulos","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2026.107452_bb0120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.neurobiolaging.2025.02.008","article-title":"CSF \u03b1-synuclein aggregation is associated with APOE \u03b54 and progressive cognitive decline in Alzheimer\u2019s disease","volume":"150","author":"Qiang","year":"2025","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.nbd.2026.107452_bb0125","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41591-023-02449-7","article-title":"Clinical effects of Lewy body pathology in cognitively impaired individuals","volume":"29","author":"Quadalti","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2026.107452_bb0130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","article-title":"Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies","volume":"140","author":"Rossi","year":"2020","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2026.107452_bb0135","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","article-title":"Development of a biochemical diagnosis of Parkinson disease by detection of \u03b1-synuclein misfolded aggregates in cerebrospinal fluid","volume":"74","author":"Shahnawaz","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.nbd.2026.107452_bb0140","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.clinbiochem.2019.05.006","article-title":"Method comparison study of the Elecsys\u00ae \u03b2-amyloid (1-42) CSF assay versus comparator assays and LC-MS\/MS","volume":"72","author":"Shaw","year":"2019","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.nbd.2026.107452_bb0145","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1212\/WNL.0b013e3181f39a78","article-title":"CSF amyloid \u03b2 1-42 predicts cognitive decline in Parkinson disease","volume":"75","author":"Siderowf","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2026.107452_bb0150","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","article-title":"Assessment of heterogeneity among participants in the Parkinson\u2019s progression markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study","volume":"22","author":"Siderowf","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2026.107452_bb0155","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","article-title":"A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research","volume":"23","author":"Simuni","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2026.107452_bb0160","first-page":"1234","article-title":"Neuropathology of dementia in patients with Parkinson's disease: a systematic review of autopsy studies","volume":"90","author":"Smith","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.nbd.2026.107452_bb0165","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1056\/NEJMra2401857","article-title":"Parkinson\u2019s disease","volume":"391","author":"Tanner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nbd.2026.107452_bb0170","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00401-015-1526-9","article-title":"Pathological \u03b1-synuclein distribution in subjects with coincident Alzheimer\u2019s and Lewy body pathology","volume":"131","author":"Toledo","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2026.107452_bb0175","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.1002\/alz.13858","article-title":"A cross-sectional study of \u03b1-synuclein seed amplification assay in Alzheimer\u2019s disease neuroimaging initiative: prevalence and associations with Alzheimer\u2019s disease biomarkers and cognitive function","volume":"20","author":"Tosun","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nbd.2026.107452_bb0180","doi-asserted-by":"crossref","first-page":"8444","DOI":"10.1002\/alz.14276","article-title":"Association of CSF \u03b1-synuclein seed amplification assay positivity with disease progression and cognitive decline: a longitudinal Alzheimer\u2019s disease neuroimaging Initiative study","volume":"20","author":"Tosun","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nbd.2026.107452_bb0185","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/jamaneurol.2013.600","article-title":"APOE \u03b54 increases risk for dementia in pure synucleinopathies","volume":"70","author":"Tsuang","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.nbd.2026.107452_bb0190","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/mds.26170","article-title":"Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson\u2019s disease","volume":"30","author":"Weintraub","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2026.107452_bb0195","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neurobiolaging.2023.07.011","article-title":"Clinical and neurochemical correlates of the APOE genotype in early-stage Parkinson\u2019s disease","volume":"131","author":"Zenuni","year":"2023","journal-title":"Neurobiol. Aging"}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096999612600197X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096999612600197X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:59:20Z","timestamp":1790683160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096999612600197X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"alternative-id":["S096999612600197X"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2026.107452","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of CSF \u03b1-synuclein seed amplification assay and amyloid-\u03b242 predicts cognitive decline in Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2026.107452","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107452"}}